Your cart is empty
Browse transcripts and add items to get started.
CVS Health delivered a strong first-quarter beat on both revenue and earnings, with adjusted EPS of $2.57 on revenues of $100.4 billion, prompting a $0.30 raise to full-year adjusted EPS guidance. The Health Care Benefits segment drove the upside, with Aetna's medical benefit ratio of 84.6% coming in well below prior-year levels amid disciplined cost management and favorable prior-year development.
Performance Highlights
CVS Health reported first-quarter 2026 revenues of $100.4 billion, up 6.2% year-over-year, with adjusted EPS of $2.57 representing a 14% increase from the prior-year quarter and surpassing consensus expectations. Adjusted operating income reached approximately $5.2 billion, a 12% improvement driven primarily by a more than $1 billion year-over-year gain in the Health Care Benefits segment, where Aetna's medical benefit ratio improved sharply to 84.6% from 87.3%.
The standout operating driver was Aetna's margin recovery, with favorable prior-year development and pockets of core outperformance in government business lifting HCB adjusted operating income to approximately $3 billion. Health Services revenues rose 11% to $48.2 billion on pharmacy drug mix and brand inflation, while Pharmacy and Consumer Wellness posted a 7% same-store prescription volume gain and retail script share above 29%, partially offset by reimbursement pressure and milder seasonal illness.
Management Outlook and Forward Catalysts
Management raised full-year 2026 adjusted EPS guidance to $7.30–$7.50 and total revenue guidance to at least $405 billion, while lifting cash flow from operations guidance to at least $9.5 billion, signaling confidence in durable earnings recovery rather than a one-quarter anomaly. The HCB full-year adjusted operating income range was increased by $420 million to $4.00–$4.34 billion, and Aetna leadership reaffirmed a target margin recovery trajectory with 2028 as the stated destination.
Bulls will focus on whether Aetna's MBR improvement reflects structural cost discipline or one-time reserve releases, and whether the Stelara biosimilar conversion and Health100 platform launch can generate incremental PBM and consumer revenue. Bears will watch Medicare Advantage rate adequacy for 2027, ongoing Health Services client price concessions, PBM regulatory risk from federal and state legislation, and the pace of leverage reduction before share repurchases resume.
Adjusted EPS vs. consensus breakdown — primary performance driver, segment revenue contribution, and gross margin trajectory relative to prior guidance...
Segment-by-segment revenue analysis, margin profile, and management commentary on demand trajectory vs. consensus range expectations...
Forward guidance implications for the sector, supply chain read-throughs, and investment implications for the broader competitive landscape...
